See more : Bango PLC (BGOPF) Income Statement Analysis – Financial Results
Complete financial analysis of SCYNEXIS, Inc. (SCYX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SCYNEXIS, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Waseco Resources Inc. (WSRUF) Income Statement Analysis – Financial Results
- American National Bankshares Inc. (AMNB) Income Statement Analysis – Financial Results
- I-Freek Mobile Inc. (3845.T) Income Statement Analysis – Financial Results
- Aarti Pharmalabs Limited (AARTIPHARM.BO) Income Statement Analysis – Financial Results
- MetroGlobal Limited (METROGLOBL.BO) Income Statement Analysis – Financial Results
SCYNEXIS, Inc. (SCYX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.scynexis.com
About SCYNEXIS, Inc.
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 140.14M | 5.09M | 13.16M | 0.00 | 121.00K | 257.00K | 257.00K | 257.00K | 257.00K | 1.26M | 16.86M | 16.84M |
| Cost of Revenue | 15.62M | 628.00K | 312.00K | 303.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.45M | 16.31M | 14.36M |
| Gross Profit | 124.52M | 4.46M | 12.85M | -303.00K | 121.00K | 257.00K | 257.00K | 257.00K | 257.00K | -14.19M | 552.00K | 2.47M |
| Gross Profit Ratio | 88.85% | 87.66% | 97.63% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | -1,129.78% | 3.27% | 14.69% |
| Research & Development | 30.93M | 27.26M | 23.77M | 36.52M | 38.39M | 21.56M | 18.33M | 20.08M | 16.44M | 8.29M | 4.36M | 8.93M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.68M | 8.25M | 8.00M | 12.17M | 7.57M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 48.00K | 0.00 | 0.00 |
| SG&A | 20.92M | 62.96M | 49.92M | 14.63M | 10.65M | 8.68M | 8.25M | 8.00M | 12.17M | 7.62M | 4.38M | 4.74M |
| Other Expenses | 0.00 | 3.00K | -13.00K | -334.00K | 538.00K | 0.00 | 0.00 | 0.00 | 0.00 | -10.00K | 4.38M | 12.00K |
| Operating Expenses | 51.85M | 90.22M | 73.68M | 50.82M | 49.04M | 30.24M | 26.58M | 28.07M | 28.61M | 15.90M | 8.74M | 13.67M |
| Cost & Expenses | 67.47M | 90.85M | 73.99M | 50.82M | 49.04M | 30.24M | 26.58M | 28.07M | 28.61M | 15.90M | 25.05M | 28.03M |
| Interest Income | 3.95M | 1.42M | 24.00K | 189.00K | 805.00K | 967.00K | 386.00K | 185.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.13M | 5.20M | 2.66M | 1.18M | 986.00K | 2.05M | 1.86M | 351.00K | 11.00K | 803.00K | 11.89M | 972.00K |
| Depreciation & Amortization | 810.00K | 813.00K | 577.00K | 303.00K | 285.00K | 53.00K | 41.00K | 26.00K | 447.00K | 1.24M | 1.33M | 1.49M |
| EBITDA | 73.48M | -59.91M | -31.41M | -51.15M | -51.27M | -17.10M | -23.16M | -29.51M | -27.90M | -2.19M | -13.76M | -9.71M |
| EBITDA Ratio | 52.43% | -1,675.94% | -468.93% | 0.00% | -40,196.69% | -11,269.65% | -10,075.10% | -10,780.54% | -10,856.81% | -1,128.50% | -61.39% | -74.91% |
| Operating Income | 72.67M | -85.76M | -60.83M | -51.15M | -48.92M | -29.98M | -26.32M | -27.82M | -28.35M | -14.65M | -7.20M | -7.78M |
| Operating Income Ratio | 51.85% | -1,684.48% | -462.09% | 0.00% | -40,430.58% | -11,666.54% | -10,241.25% | -10,823.74% | -11,030.74% | -1,166.16% | -42.74% | -46.23% |
| Total Other Income/Expenses | -5.49M | 18.25M | 24.88M | -7.18M | -4.79M | 10.78M | 1.26M | -2.17M | 11.00K | 7.88M | -23.26M | -281.00K |
| Income Before Tax | 67.18M | -67.51M | -35.95M | -58.33M | -53.71M | -19.20M | -25.06M | -29.99M | -28.34M | -6.77M | -30.46M | -11.48M |
| Income Before Tax Ratio | 47.94% | -1,326.05% | -273.14% | 0.00% | -44,388.43% | -7,472.37% | -9,750.97% | -11,668.87% | -11,026.46% | -538.93% | -180.70% | -68.17% |
| Income Tax Expense | 138.00K | -4.70M | -3.09M | -3.15M | 1.52M | -6.74M | 1.86M | 351.00K | -4.29M | -1.17M | 11.89M | 984.00K |
| Net Income | 67.04M | -62.81M | -32.87M | -55.19M | -55.23M | -12.47M | -25.06M | -29.99M | -32.62M | -4.23M | -30.46M | -11.48M |
| Net Income Ratio | 47.84% | -1,233.73% | -249.68% | 0.00% | -45,647.93% | -4,851.36% | -9,750.97% | -11,668.87% | -12,693.77% | -337.10% | -180.70% | -68.17% |
| EPS | 1.40 | -1.47 | -1.25 | -5.15 | -9.85 | -2.84 | -9.37 | -15.75 | -26.82 | -7.48 | -192.64 | -72.58 |
| EPS Diluted | 1.39 | -1.47 | -1.25 | -5.15 | -9.85 | -2.84 | -9.37 | -15.75 | -26.82 | -7.13 | -192.64 | -72.58 |
| Weighted Avg Shares Out | 47.85M | 42.61M | 26.38M | 10.72M | 5.61M | 4.39M | 2.67M | 1.90M | 1.22M | 566.33K | 158.13K | 158.13K |
| Weighted Avg Shares Out (Dil) | 48.39M | 42.61M | 26.38M | 10.72M | 5.61M | 4.39M | 2.67M | 1.90M | 1.22M | 593.71K | 158.13K | 158.13K |
3 Stocks Under $10 With Mammoth Growth Prospects
Finding good prospects is like hunting gold in the fast-paced world of investing. Three stocks stand out in this hunt, all under $10, with significant growth potential.
SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
JERSEY CITY, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the first quarter ended March 31, 2024.
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
JERSEY CITY, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second generation fungerp...
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second-generation fungerp candidate...
Scynexis: Update Following Restructuring Of GSK Deal
Scynexis stock price has resumed the downtrend following a restructuring of the GSK deal associated with considerable reduction of pending milestones. SCYX ended 2023 with $98M, but is still trading at a $54M market cap. Cash runway is beyond 2...
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
JERSEY CITY, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the year ended December 31, 2023.
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
JERSEY CITY, N.J., Jan. 29, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second generation fungerp...
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SCYNEXIS, Inc. ("SCYNEXIS" or "the Company") (NASDAQ:SCYX) for violations of §§10(b) and...
Final SCYX Investor Deadline: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK , Jan. 8, 2024 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against SCYNEXIS, Inc. ("Scynexis" or "the Company") (NASDAQ: SCYX) and certain of...
SCYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, Jan. 7, 2024 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against SCYNEXIS, Inc. ("Scynexis" or "the Company") (NASDAQ: SCYX) and certain of...
Source: https://incomestatements.info
Category: Stock Reports